Search

Your search keyword '"Gurioli C."' showing total 125 results
Start Over Author "Gurioli C." Publication Year Range Last 10 years
125 results on '"Gurioli C."'

4. A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis

Author

Stingeni, L., Bianchi, L., Antonelli, E., Caroppo, E. S., Ferrucci, S. M., Gurioli, C., Ortoncelli, M., Fabbrocini, G., Nettis, E., Schena, D., Napolitano, M., Gola, M., Bonzano, L., Rossi, M., Belloni Fortina, A., Balato, A., Peris, Ketty, Foti, C., Guarneri, F., Romanelli, M., Patruno, C., Savoia, P., Esposito, M., Russo, F., Errichetti, E., Bianchelli, T., Pellacani, G., Feliciani, C., Offidani, A., Corazza, M., Micali, G., Milanesi, N., Malara, G., Chiricozzi, Andrea, Tramontana, M., Hansel, K., Buligan, C., Caroppo, F., Bello, G. D., Dastoli, S., Di Brizzi, E. V., Del Giudice, M. B. D. F., Diluvio, L., Fargnoli, Maria Concetta, Gelmetti, A., Giacchetti, A., Grieco, T., Iannone, M., Macchia, L., Marietti, R., Musumeci, M. L., Motolese, A., Neri, I., Radi, G., Ribero, S., Romita, P., Tavecchio, S., Tronconi, G., Veronese, F., Peris K. (ORCID:0000-0002-5237-0463), Chiricozzi A. (ORCID:0000-0002-6739-0387), Fargnoli M. C., Stingeni, L., Bianchi, L., Antonelli, E., Caroppo, E. S., Ferrucci, S. M., Gurioli, C., Ortoncelli, M., Fabbrocini, G., Nettis, E., Schena, D., Napolitano, M., Gola, M., Bonzano, L., Rossi, M., Belloni Fortina, A., Balato, A., Peris, Ketty, Foti, C., Guarneri, F., Romanelli, M., Patruno, C., Savoia, P., Esposito, M., Russo, F., Errichetti, E., Bianchelli, T., Pellacani, G., Feliciani, C., Offidani, A., Corazza, M., Micali, G., Milanesi, N., Malara, G., Chiricozzi, Andrea, Tramontana, M., Hansel, K., Buligan, C., Caroppo, F., Bello, G. D., Dastoli, S., Di Brizzi, E. V., Del Giudice, M. B. D. F., Diluvio, L., Fargnoli, Maria Concetta, Gelmetti, A., Giacchetti, A., Grieco, T., Iannone, M., Macchia, L., Marietti, R., Musumeci, M. L., Motolese, A., Neri, I., Radi, G., Ribero, S., Romita, P., Tavecchio, S., Tronconi, G., Veronese, F., Peris K. (ORCID:0000-0002-5237-0463), Chiricozzi A. (ORCID:0000-0002-6739-0387), and Fargnoli M. C.

Abstract

na

Published
2023

6. WSES/GAIS/SIS-E/WSIS/AAST global clinical pathways for patients with intra-abdominal infections

Author

Sartelli, M, Coccolini, F, Kluger, Y, Agastra, E, Abu-Zidan, F, Abbas, A, Ansaloni, L, Adesunkanmi, A, Atanasov, B, Augustin, G, Bala, M, Baraket, O, Baral, S, Biffl, W, Boermeester, M, Ceresoli, M, Cerutti, E, Chiara, O, Cicuttin, E, Chiarugi, M, Coimbra, R, Colak, E, Corsi, D, Cortese, F, Cui, Y, Damaskos, D, de' Angelis, N, Delibegovic, S, Demetrashvili, Z, De Simone, B, de Jonge, S, Dhingra, S, Di Bella, S, Di Marzo, F, Di Saverio, S, Dogjani, A, Duane, T, Enani, M, Fugazzola, P, Galante, J, Gachabayov, M, Ghnnam, W, Gkiokas, G, Gomes, C, Griffiths, E, Hardcastle, T, Hecker, A, Herzog, T, Kabir, S, Karamarkovic, A, Khokha, V, Kim, P, Kim, J, Kirkpatrick, A, Kong, V, Koshy, R, Kryvoruchko, I, Inaba, K, Isik, A, Iskandar, K, Ivatury, R, Labricciosa, F, Lee, Y, Leppaniemi, A, Litvin, A, Luppi, D, Machain, G, Maier, R, Marinis, A, Marmorale, C, Marwah, S, Mesina, C, Moore, E, Moore, F, Negoi, I, Olaoye, I, Ordonez, C, Ouadii, M, Peitzman, A, Perrone, G, Pikoulis, M, Pintar, T, Pipitone, G, Podda, M, Rasa, K, Ribeiro, J, Rodrigues, G, Rubio-Perez, I, Sall, I, Sato, N, Sawyer, R, Segovia Lohse, H, Sganga, G, Shelat, V, Stephens, I, Sugrue, M, Tarasconi, A, Tochie, J, Tolonen, M, Tomadze, G, Ulrych, J, Vereczkei, A, Viaggi, B, Gurioli, C, Casella, C, Pagani, L, Baiocchi, G, Catena, F, Sartelli M., Coccolini F., Kluger Y., Agastra E., Abu-Zidan F. M., Abbas A. E. S., Ansaloni L., Adesunkanmi A. K., Atanasov B., Augustin G., Bala M., Baraket O., Baral S., Biffl W. L., Boermeester M. A., Ceresoli M., Cerutti E., Chiara O., Cicuttin E., Chiarugi M., Coimbra R., Colak E., Corsi D., Cortese F., Cui Y., Damaskos D., de' Angelis N., Delibegovic S., Demetrashvili Z., De Simone B., de Jonge S. W., Dhingra S., Di Bella S., Di Marzo F., Di Saverio S., Dogjani A., Duane T. M., Enani M. A., Fugazzola P., Galante J. M., Gachabayov M., Ghnnam W., Gkiokas G., Gomes C. A., Griffiths E. A., Hardcastle T. C., Hecker A., Herzog T., Kabir S. M. U., Karamarkovic A., Khokha V., Kim P. K., Kim J. I., Kirkpatrick A. W., Kong V., Koshy R. M., Kryvoruchko I. A., Inaba K., Isik A., Iskandar K., Ivatury R., Labricciosa F. M., Lee Y. Y., Leppaniemi A., Litvin A., Luppi D., Machain G. M., Maier R. V., Marinis A., Marmorale C., Marwah S., Mesina C., Moore E. E., Moore F. A., Negoi I., Olaoye I., Ordonez C. A., Ouadii M., Peitzman A. B., Perrone G., Pikoulis M., Pintar T., Pipitone G., Podda M., Rasa K., Ribeiro J., Rodrigues G., Rubio-Perez I., Sall I., Sato N., Sawyer R. G., Segovia Lohse H., Sganga G., Shelat V. G., Stephens I., Sugrue M., Tarasconi A., Tochie J. N., Tolonen M., Tomadze G., Ulrych J., Vereczkei A., Viaggi B., Gurioli C., Casella C., Pagani L., Baiocchi G. L., Catena F., Sartelli, M, Coccolini, F, Kluger, Y, Agastra, E, Abu-Zidan, F, Abbas, A, Ansaloni, L, Adesunkanmi, A, Atanasov, B, Augustin, G, Bala, M, Baraket, O, Baral, S, Biffl, W, Boermeester, M, Ceresoli, M, Cerutti, E, Chiara, O, Cicuttin, E, Chiarugi, M, Coimbra, R, Colak, E, Corsi, D, Cortese, F, Cui, Y, Damaskos, D, de' Angelis, N, Delibegovic, S, Demetrashvili, Z, De Simone, B, de Jonge, S, Dhingra, S, Di Bella, S, Di Marzo, F, Di Saverio, S, Dogjani, A, Duane, T, Enani, M, Fugazzola, P, Galante, J, Gachabayov, M, Ghnnam, W, Gkiokas, G, Gomes, C, Griffiths, E, Hardcastle, T, Hecker, A, Herzog, T, Kabir, S, Karamarkovic, A, Khokha, V, Kim, P, Kim, J, Kirkpatrick, A, Kong, V, Koshy, R, Kryvoruchko, I, Inaba, K, Isik, A, Iskandar, K, Ivatury, R, Labricciosa, F, Lee, Y, Leppaniemi, A, Litvin, A, Luppi, D, Machain, G, Maier, R, Marinis, A, Marmorale, C, Marwah, S, Mesina, C, Moore, E, Moore, F, Negoi, I, Olaoye, I, Ordonez, C, Ouadii, M, Peitzman, A, Perrone, G, Pikoulis, M, Pintar, T, Pipitone, G, Podda, M, Rasa, K, Ribeiro, J, Rodrigues, G, Rubio-Perez, I, Sall, I, Sato, N, Sawyer, R, Segovia Lohse, H, Sganga, G, Shelat, V, Stephens, I, Sugrue, M, Tarasconi, A, Tochie, J, Tolonen, M, Tomadze, G, Ulrych, J, Vereczkei, A, Viaggi, B, Gurioli, C, Casella, C, Pagani, L, Baiocchi, G, Catena, F, Sartelli M., Coccolini F., Kluger Y., Agastra E., Abu-Zidan F. M., Abbas A. E. S., Ansaloni L., Adesunkanmi A. K., Atanasov B., Augustin G., Bala M., Baraket O., Baral S., Biffl W. L., Boermeester M. A., Ceresoli M., Cerutti E., Chiara O., Cicuttin E., Chiarugi M., Coimbra R., Colak E., Corsi D., Cortese F., Cui Y., Damaskos D., de' Angelis N., Delibegovic S., Demetrashvili Z., De Simone B., de Jonge S. W., Dhingra S., Di Bella S., Di Marzo F., Di Saverio S., Dogjani A., Duane T. M., Enani M. A., Fugazzola P., Galante J. M., Gachabayov M., Ghnnam W., Gkiokas G., Gomes C. A., Griffiths E. A., Hardcastle T. C., Hecker A., Herzog T., Kabir S. M. U., Karamarkovic A., Khokha V., Kim P. K., Kim J. I., Kirkpatrick A. W., Kong V., Koshy R. M., Kryvoruchko I. A., Inaba K., Isik A., Iskandar K., Ivatury R., Labricciosa F. M., Lee Y. Y., Leppaniemi A., Litvin A., Luppi D., Machain G. M., Maier R. V., Marinis A., Marmorale C., Marwah S., Mesina C., Moore E. E., Moore F. A., Negoi I., Olaoye I., Ordonez C. A., Ouadii M., Peitzman A. B., Perrone G., Pikoulis M., Pintar T., Pipitone G., Podda M., Rasa K., Ribeiro J., Rodrigues G., Rubio-Perez I., Sall I., Sato N., Sawyer R. G., Segovia Lohse H., Sganga G., Shelat V. G., Stephens I., Sugrue M., Tarasconi A., Tochie J. N., Tolonen M., Tomadze G., Ulrych J., Vereczkei A., Viaggi B., Gurioli C., Casella C., Pagani L., Baiocchi G. L., and Catena F.

Abstract

Intra-abdominal infections (IAIs) are common surgical emergencies and have been reported as major contributors to non-trauma deaths in hospitals worldwide. The cornerstones of effective treatment of IAIs include early recognition, adequate source control, appropriate antimicrobial therapy, and prompt physiologic stabilization using a critical care environment, combined with an optimal surgical approach. Together, the World Society of Emergency Surgery (WSES), the Global Alliance for Infections in Surgery (GAIS), the Surgical Infection Society-Europe (SIS-E), the World Surgical Infection Society (WSIS), and the American Association for the Surgery of Trauma (AAST) have jointly completed an international multi-society document in order to facilitate clinical management of patients with IAIs worldwide building evidence-based clinical pathways for the most common IAIs. An extensive non-systematic review was conducted using the PubMed and MEDLINE databases, limited to the English language. The resulting information was shared by an international task force from 46 countries with different clinical backgrounds. The aim of the document is to promote global standards of care in IAIs providing guidance to clinicians by describing reasonable approaches to the management of IAIs.

Published
2021

10. Impact of Surgical Approach on Patient-Reported Outcomes after Radical Prostatectomy: A Propensity Score-Weighted Analysis from a Multicenter, Prospective, Observational Study (The Pros-IT CNR Study)

Author

Antonelli, A., Palumbo, C., Noale, M., Porreca, A., Maggi, S., Simeone, C., Bassi, P., Bertoni, F., Bracarda, S., Buglione, M., Conti, G. N., Corvò, R., Gacci, M., Mirone, V., Montironi, R., Triggiani, L., Tubaro, A., Artibani, W., Crepaldi, G., Graziotti, P., Russi, E., Magrini, Stefano, Muto, M., Pecoraro, G., Ricardi, S., Zagonel, U., Alitto, Anna, Ambrosi, R., Aristei, E., Barbieri, C., Bardari, M., Bardoscia, F., Barra, L., Bartoncini, S., Basso, S., Becherini, U., Bellavita, C., Bergamaschi, R., Berlingheri, F., Berruti, S., Borghesi, M., Bortolus, R., Borzillo, V., Bosetti, D., Bove, G., Bove, P., Brausi, M., Bruni, A., Bruno, G., Brunocilla, E., Buffoli, A., Buttigliero, C., Cacciamani, G., Caldiroli, M., Cardo, G., Carmignani, G., Carrieri, G., Castelli, E., Castrezzati, E., Catalano, G., Cattarino, S., Catucci, F., Cavallini, F. D., Ceccarini, O., Celia, A., Chiancone, F., Chini, T., Cianci, C., Cisternino, A., Collura, D., Corbella, F., Corinti, M., Corsi, P., Cortese, F., Corti, L., Cosimo, De, Cristiano, N., D'Angelillo, O., Pozzo, Da, D'Agostino, L., D'Elia, D., Dandrea, C., Angelis, De, Cobelli, De, Concilio, De, Lisa, De, Luca, De, Stefani, De, Deantoni, A., C. L., Degli, Esposti, Destito, C., Detti, A., Muzio, Di, Stasio, Di, Stefano, Di, Trapani, Di, Difino, D., Falivene, G., Farullo, S., Fedelini, G., Ferrari, P., Ferraù, I., Ferro, F., Fodor, M., Fontana, A., Francesca, F., Francolini, F., Frata, G., Frezza, P., Gabriele, G., Galeandro, P., Garibaldi, M., Gennari, Pietro, Gentilucci, G., Giacobbe, A., Giussani, A., Giusti, L., Gontero, G., Guarneri, P., Guida, A., Gurioli, C., Huqi, A., Imbimbo, D., Ingrosso, C., Iotti, G., Italia, C., Mattina, La, Lamanna, P., Lastrucci, E., Lazzari, L., Liberale, G., Liguori, F., Lisi, G., Lohr, R., Lombardo, F., Lovisolo, R., J. A. J., Ludovico, Giuseppe, Macchione, M., Maggio, N., Malizia, F., Manasse, M., Mandoliti, G., Mantini, G., Marafioti, G., Marciello, L., Marconi, Alberto, Martilotta, M., Marzano, A., Masciullo, S., Maso, S., Massenzo, G., Mazzeo, A., Mearini, E., Medoro, L., Molè, S., Monesi, R., Montanari, G., Montefiore, E., Montesi, F., Morgia, G., Moro, G., Muscas, G., Musio, G., Muto, D., Muzzonigro, P., Napodano, G., Negro, G., Nidini, C. L. A., Ntreta, M., Orsatti, M., Palazzolo, M., Parisi, I., Parma, A., Pavan, P., Pericolini, N., Pinto, M., Pistone, F., Pizzuti, A., Platania, V., Polli, A., Pomara, C., Ponti, G., Porcaro, E., Porpiglia, A. B., Pugliese, F., Pycha, D., Raguso, A., Rampini, G., Randone, Donato, Roboldi, F., Roscigno, V., Ruggieri, M., Ruoppo, M. P., Sanseverino, G., Santacaterina, R., Santarsieri, A., Santoni, M., Scagliarini, R., Scagliotti, Giorgio, Scanzi, V., Scarcia, M., Schiavina, M., Sciarra, R., Sciorio, A., Scolaro, C., Scuzzarella, T., Selvaggio, S., Serao, O., Serni, A., Signor, S., Silvani, M. A., Silvano, M., Silvestris, G., Simone, F., Spagnoletti, V., Spinelli, Matteo, Squillace, G., Tombolini, L., Toninelli, V., Trinchieri, M., Trodella, A., Trodella, L. E., Trombetta, L., Tronnolone, C., Tucci, L., Urzì, M., Valdagni, D., Valeriani, R., Vanoli, M., Vitali, M., Volpe, E., Zaramella, A., Zeccolini, S., Zini, G., Antonelli, A., Palumbo, C., Noale, M., Porreca, A., Maggi, S., Simeone, C., Bassi, P., Bertoni, F., Bracarda, S., Buglione, M., Conti, G. N., Corvo, R., Gacci, M., Mirone, V., Montironi, R., Triggiani, L., Tubaro, A., Artibani, W., Crepaldi, G., Graziotti, P., Russi, E., Magrini Stefano, M., Muto, G., Pecoraro, S., Ricardi, U., Zagonel, V., Alitto Anna, R., Ambrosi, E., Aristei, C., Barbieri, M., Bardari, F., Bardoscia, L., Barra, S., Bartoncini, S., Basso, U., Becherini, C., Bellavita, R., Bergamaschi, F., Berlingheri, S., Berruti, A., Borghesi, M., Bortolus, R., Borzillo, V., Bosetti, D., Bove, G., Bove, P., Brausi, M., Bruni, A., Bruno, G., Brunocilla, E., Buffoli, A., Buttigliero, C., Cacciamani, G., Caldiroli, M., Cardo, G., Carmignani, G., Carrieri, G., Castelli, E., Castrezzati, E., Catalano, G., Cattarino, S., Catucci, F., Cavallini, F. D., Ceccarini, O., Celia, A., Chiancone, F., Chini, T., Cianci, C., Cisternino, A., Collura, D., Corbella, F., Corinti, M., Corsi, P., Cortese, F., Corti, L., de Cosimo, N., Cristiano, O., D'Angelillo, R., Da Pozzo, L., D'Agostino, D., D'Elia, C., Dandrea, M., De Angelis, M., De Angelis, P., De Cobelli, O., De Concilio, B., De Lisa, A., De Luca, S., De Stefani, A., Deantoni, C. L., Degli Esposti, C., Destito, A., Detti, B., Di Muzio, N., Di Stasio, A., Di Stefano, C., Di Trapani, D., Difino, G., Falivene, S., Farullo, G., Fedelini, P., Ferrari, I., Ferrau, F., Ferro, M., Fodor, A., Fontana, F., Francesca, F., Francolini, G., Frata, P., Frezza, G., Gabriele, P., Galeandro, M., Garibaldi, E., Gennari Pietro, G., Gentilucci, A., Giacobbe, A., Giussani, L., Giusti, G., Gontero, P., Guarneri, A., Guida, C., Gurioli, A., Huqi, D., Imbimbo, C., Ingrosso, G., Iotti, C., Italia, C., La Mattina, P., Lamanna, E., Lastrucci, L., Lazzari, G., Liberale, F., Liguori, G., Lisi, R., Lohr, F., Lombardo, R., Lovisolo, J. A. J., Ludovico Giuseppe, M., Macchione, N., Maggio, F., Malizia, M., Manasse, G., Mandoliti, G., Mantini, G., Marafioti, L., Marciello, L., Marconi Alberto, M., Martilotta, A., Marzano, S., Masciullo, S., Maso, G., Massenzo, A., Mazzeo, E., Mearini, L., Medoro, S., Mole, R., Monesi, G., Montanari, E., Montefiore, F., Montesi, G., Morgia, G., Moro, G., Muscas, G., Musio, D., Muto, P., Muzzonigro, G., Napodano, G., Negro, C. L. A., Nidini, M., Ntreta, M., Orsatti, M., Palazzolo, C., Palumbo, I., Parisi, A., Parma, P., Pavan, N., Pericolini, M., Pinto, F., Pistone, A., Pizzuti, V., Platania, A., Polli, C., Pomara, G., Ponti, E., Porcaro, A. B., Porpiglia, F., Pugliese, D., Pycha, A., Raguso, G., Rampini, A., Randone Donato, F., Roboldi, V., Roscigno, M., Ruggieri, M. P., Ruoppo, G., Sanseverino, R., Santacaterina, A., Santarsieri, M., Santoni, R., Scagliarini, S., Scagliotti Giorgio, V., Scanzi, M., Scarcia, M., Schiavina, R., Sciarra, A., Sciorio, C., Scolaro, T., Scuzzarella, S., Selvaggio, O., Serao, A., Serni, S., Signor, M. A., Silvani, M., Silvano, G., Silvestris, F., Simone, V., Spagnoletti, G., Spinelli Matteo, G., Squillace, L., Tombolini, V., Toninelli, M., Trinchieri, A., Trodella, L. E., Trodella, L., Trombetta, C., Tronnolone, L., Tucci, M., Urzi, D., Valdagni, R., Valeriani, M., Vanoli, M., Vitali, E., Volpe, A., Zaramella, S., Zeccolini, G., Zini, G., Antonelli, A, Palumbo, C, Noale, M, Porreca, A, Maggi, S, Simeone, C, Bassi, P, Bertoni, F, Bracarda, S, Buglione, M, Conti, G, Corvo, R, Gacci, M, Mirone, V, Montironi, R, Triggiani, L, Tubaro, A, Artibani, W, Crepaldi, G, Graziotti, P, Russi, E, Magrini Stefano, M, Muto, G, Pecoraro, S, Ricardi, U, Zagonel, V, Alitto Anna, R, Ambrosi, E, Aristei, C, Barbieri, M, Bardari, F, Bardoscia, L, Barra, S, Bartoncini, S, Basso, U, Becherini, C, Bellavita, R, Bergamaschi, F, Berlingheri, S, Berruti, A, Borghesi, M, Bortolus, R, Borzillo, V, Bosetti, D, Bove, G, Bove, P, Brausi, M, Bruni, A, Bruno, G, Brunocilla, E, Buffoli, A, Buttigliero, C, Cacciamani, G, Caldiroli, M, Cardo, G, Carmignani, G, Carrieri, G, Castelli, E, Castrezzati, E, Catalano, G, Cattarino, S, Catucci, F, Cavallini, F, Ceccarini, O, Celia, A, Chiancone, F, Chini, T, Cianci, C, Cisternino, A, Collura, D, Corbella, F, Corinti, M, Corsi, P, Cortese, F, Corti, L, de Cosimo, N, Cristiano, O, D'Angelillo, R, Da Pozzo, L, D'Agostino, D, D'Elia, C, Dandrea, M, De Angelis, M, De Angelis, P, De Cobelli, O, De Concilio, B, De Lisa, A, De Luca, S, De Stefani, A, Deantoni, C, Degli Esposti, C, Destito, A, Detti, B, Di Muzio, N, Di Stasio, A, Di Stefano, C, Di Trapani, D, Difino, G, Falivene, S, Farullo, G, Fedelini, P, Ferrari, I, Ferrau, F, Ferro, M, Fodor, A, Fontana, F, Francesca, F, Francolini, G, Frata, P, Frezza, G, Gabriele, P, Galeandro, M, Garibaldi, E, Gennari Pietro, G, Gentilucci, A, Giacobbe, A, Giussani, L, Giusti, G, Gontero, P, Guarneri, A, Guida, C, Gurioli, A, Huqi, D, Imbimbo, C, Ingrosso, G, Iotti, C, Italia, C, La Mattina, P, Lamanna, E, Lastrucci, L, Lazzari, G, Liberale, F, Liguori, G, Lisi, R, Lohr, F, Lombardo, R, Lovisolo, J, Ludovico Giuseppe, M, Macchione, N, Maggio, F, Malizia, M, Manasse, G, Mandoliti, G, Mantini, G, Marafioti, L, Marciello, L, Marconi Alberto, M, Martilotta, A, Marzano, S, Masciullo, S, Maso, G, Massenzo, A, Mazzeo, E, Mearini, L, Medoro, S, Mole, R, Monesi, G, Montanari, E, Montefiore, F, Montesi, G, Morgia, G, Moro, G, Muscas, G, Musio, D, Muto, P, Muzzonigro, G, Napodano, G, Negro, C, Nidini, M, Ntreta, M, Orsatti, M, Palazzolo, C, Palumbo, I, Parisi, A, Parma, P, Pavan, N, Pericolini, M, Pinto, F, Pistone, A, Pizzuti, V, Platania, A, Polli, C, Pomara, G, Ponti, E, Porcaro, A, Porpiglia, F, Pugliese, D, Pycha, A, Raguso, G, Rampini, A, Randone Donato, F, Roboldi, V, Roscigno, M, Ruggieri, M, Ruoppo, G, Sanseverino, R, Santacaterina, A, Santarsieri, M, Santoni, R, Scagliarini, S, Scagliotti Giorgio, V, Scanzi, M, Scarcia, M, Schiavina, R, Sciarra, A, Sciorio, C, Scolaro, T, Scuzzarella, S, Selvaggio, O, Serao, A, Serni, S, Signor, M, Silvani, M, Silvano, G, Silvestris, F, Simone, V, Spagnoletti, G, Spinelli Matteo, G, Squillace, L, Tombolini, V, Toninelli, M, Trinchieri, A, Trodella, L, Trombetta, C, Tronnolone, L, Tucci, M, Urzi, D, Valdagni, R, Valeriani, M, Vanoli, M, Vitali, E, Volpe, A, Zaramella, S, Zeccolini, G, and Zini, G

Subjects
Male, Patient-reported outcome measures, Prostate cancer, Quality of life, Radical prostatectomy, Sexual function, Urinary function, Patient Reported Outcome Measure, medicine.medical_treatment, 030232 urology & nephrology, Longitudinal Studie, Aged, Data Collection, Humans, Italy, Longitudinal Studies, Middle Aged, Patient Reported Outcome Measures, Prospective Studies, Prostate, Prostatectomy, Prostatic Neoplasms, Quality of Life, Retrospective Studies, Robotic Surgical Procedures, Surveys and Questionnaires, Treatment Outcome, Propensity Score, 0302 clinical medicine, Retrospective Studie, Medicine, Surveys and Questionnaire, Prospective cohort study, Patient-reported outcome measure, 030220 oncology & carcinogenesis, Human, medicine.medical_specialty, Robotic Surgical Procedure, Urology, 03 medical and health sciences, Clinical significance, business.industry, Retrospective cohort study, Prospective Studie, Propensity score matching, Prostatic Neoplasm, Observational study, business
Abstract

Background: To report health-related quality of life outcomes as assessed by validated patient-reported outcome measures (PROMs) after radical prostatectomy (RP). ­Methods: This study analyzed patients treated with RP within The PROState cancer monitoring in Italy, from the National Research Council (Pros-IT CNR). Italian versions of Short-Form Heath Survey and university of California los Angeles-prostate cancer index questionnaires were administered. PROMs were physical composite scores, mental composite scores and urinary, bowel, sexual functions and bothers (UF/B, BF/B, SF/B). Baseline unbalances were controlled with propensity scores and stabilized inverse weights; differences in PROMs between different RP approaches were estimated by mixed models. Results: Of 541 patients treated with RP, 115 (21%) received open RP (ORP), 90 (17%) laparoscopic RP (LRP) and 336 (61%) robot-assisted RP (RARP). At head-to-head ­comparisons, RARP showed higher 12-month UF vs. LRP (interaction treatment * time p = 0.03) and 6-month SF vs. ORP (p < 0.001). At 12-month from surgery, 67, 73 and 79% of patients used no pad for urinary loss in ORP, LRP and RARP respectively (no differences for each comparison). Conversely, 16, 27 and 40% of patients declared erections firm enough for sexual intercourse in ORP, LRP and RARP respectively (only significant difference for ORP vs. RARP, p = 0.0004). Conclusions: Different RP approaches lead to significant variations in urinary and sexual PROMs, with a general trend in favour of RARP. However, their clinical significance seems limited.

Published
2019

13. Living with Chronic Spontaneous Urticaria in Italy: A Narrative Medicine Project to Improve the Pathway of Patient Care

Author

Cappuccio, A, primary, Limonta, T, additional, Parodi, A, additional, Cristaudo, A, additional, Bugliaro, F, additional, Cannavò, S, additional, Rossi, O, additional, Gurioli, C, additional, Vignoli, A, additional, Parente, R, additional, Iemoli, E, additional, Caldarola, G, additional, Pità, O, additional, Nuzzo, S, additional, Cancian, M, additional, Potenza, C, additional, Caminati, M, additional, Stingeni, L, additional, Saraceno, R, additional, Trevisini, S, additional, Piccirillo, A, additional, Sciarrone, C, additional, Panebianco, R, additional, Gola, M, additional, Costanzo, A, additional, Grieco, T, additional, Massaroni, K, additional, Reale, L, additional, and Marini, M, additional

Published
2017
Full Text
View/download PDF

17. WSES/GAIS/SIS-E/WSIS/AAST global clinical pathways for patients with intra-abdominal infections

Author

Cristian Mesina, Oussama Baraket, Arda Isik, Iyiade Olaoye, Tadeja Pintar, Wagih Ghnnam, Andreas Hecker, Ionut Negoi, Andrey Litvin, A R K Adesunkanmi, Julival Ribeiro, Stijn W. de Jonge, Norio Sato, Carlos Augusto Gomes, Manos Pikoulis, Federico Coccolini, Yeong Yeh Lee, Frederick A. Moore, Gustavo M. Machain, Francesco Cortese, Elif Colak, Luca Ansaloni, Daniela Corsi, Enrico Cicuttin, Fikri M. Abu-Zidan, Fausto Catena, Andrew W. Kirkpatrick, Raul Coimbra, I. A. Kryvoruchko, Chiara Gurioli, Paola Fugazzola, Gabriele Sganga, András Vereczkei, Sanjay Marwah, Kenji Inaba, Agron Dogjani, Antonio Tarasconi, Elisabetta Cerutti, Rao R. Ivatury, Ibrahima Sall, Michael Sugrue, Francesco M. Labricciosa, Marco Ceresoli, Renol M. Koshy, Jae Il Kim, Goran Augustin, Mauro Podda, Therese M. Duane, Katia Iskandar, Osvaldo Chiara, Dimitris Damaskos, Timothy Craig Hardcastle, Yunfeng Cui, Vishal G Shelat, Joel Noutakdie Tochie, Andrew B. Peitzman, Sameer Dhingra, Miklosh Bala, Ashraf Abbas, Samir Delibegovic, Leonardo Pagani, George Gkiokas, Claudio Casella, Mahir Gachabayov, Gabriel Rodrigues, Stefano Di Bella, Vladimir Khokha, Kemal Rasa, Nicola de’ Angelis, Ernest E. Moore, Robert G. Sawyer, Ronald V. Maier, Yoram Kluger, Ines Rubio-Perez, Victor Y. Kong, Gennaro Perrone, Francesco Di Marzo, Jan Ulrych, Gian Luca Baiocchi, Matti Tolonen, Athanasios Marinis, Cristina Marmorale, G. Tomadze, Peter K. Kim, Belinda De Simone, Aleksandar Karamarkovic, Ian Stephens, Mouaqit Ouadii, Massimo Sartelli, Davide Luppi, Boyko Atanasov, Helmut Alfredo Segovia Lohse, Ervis Agastra, Syed Mohammad Umar Kabir, Massimo Chiarugi, Carlos A. Ordoñez, Giuseppe Pipitone, Bruno Viaggi, Joseph M. Galante, Suman Baral, Ewen A. Griffiths, Mushira Enani, Marja A. Boermeester, Zaza Demetrashvili, Ari Leppäniemi, Torsten Herzog, Walter L. Biffl, Salomone Di Saverio, Sartelli, Massimo, Coccolini, Federico, Kluger, Yoram, Agastra, Ervi, Abu-Zidan, Fikri M, Abbas, Ashraf El Sayed, Ansaloni, Luca, Adesunkanmi, Abdulrashid Kayode, Atanasov, Boyko, Augustin, Goran, Bala, Miklosh, Baraket, Oussama, Baral, Suman, Biffl, Walter L, Boermeester, Marja A, Ceresoli, Marco, Cerutti, Elisabetta, Chiara, Osvaldo, Cicuttin, Enrico, Chiarugi, Massimo, Coimbra, Raul, Colak, Elif, Corsi, Daniela, Cortese, Francesco, Cui, Yunfeng, Damaskos, Dimitri, De' Angelis, Nicola, Delibegovic, Samir, Demetrashvili, Zaza, De Simone, Belinda, de Jonge, Stijn W, Dhingra, Sameer, Di Bella, Stefano, Di Marzo, Francesco, Di Saverio, Salomone, Dogjani, Agron, Duane, Therese M, Enani, Mushira Abdulaziz, Fugazzola, Paola, Galante, Joseph M, Gachabayov, Mahir, Ghnnam, Wagih, Gkiokas, George, Gomes, Carlos Augusto, Griffiths, Ewen A, Hardcastle, Timothy C, Hecker, Andrea, Herzog, Torsten, Kabir, Syed Mohammad Umar, Karamarkovic, Aleksandar, Khokha, Vladimir, Kim, Peter K, Kim, Jae Il, Kirkpatrick, Andrew W, Kong, Victor, Koshy, Renol M, Kryvoruchko, Igor A, Inaba, Kenji, Isik, Arda, Iskandar, Katia, Ivatury, Rao, Labricciosa, Francesco M, Lee, Yeong Yeh, Leppäniemi, Ari, Litvin, Andrey, Luppi, Davide, Machain, Gustavo M, Maier, Ronald V, Marinis, Athanasio, Marmorale, Cristina, Marwah, Sanjay, Mesina, Cristian, Moore, Ernest E, Moore, Frederick A, Negoi, Ionut, Olaoye, Iyiade, Ordoñez, Carlos A, Ouadii, Mouaqit, Peitzman, Andrew B, Perrone, Gennaro, Pikoulis, Mano, Pintar, Tadeja, Pipitone, Giuseppe, Podda, Mauro, Raşa, Kemal, Ribeiro, Julival, Rodrigues, Gabriel, Rubio-Perez, Ine, Sall, Ibrahima, Sato, Norio, Sawyer, Robert G, Segovia Lohse, Helmut, Sganga, Gabriele, Shelat, Vishal G, Stephens, Ian, Sugrue, Michael, Tarasconi, Antonio, Tochie, Joel Noutakdie, Tolonen, Matti, Tomadze, Gia, Ulrych, Jan, Vereczkei, Andra, Viaggi, Bruno, Gurioli, Chiara, Casella, Claudio, Pagani, Leonardo, Baiocchi, Gian Luca, Catena, Fausto, Sartelli, M, Coccolini, F, Kluger, Y, Agastra, E, Abu-Zidan, F, Abbas, A, Ansaloni, L, Adesunkanmi, A, Atanasov, B, Augustin, G, Bala, M, Baraket, O, Baral, S, Biffl, W, Boermeester, M, Ceresoli, M, Cerutti, E, Chiara, O, Cicuttin, E, Chiarugi, M, Coimbra, R, Colak, E, Corsi, D, Cortese, F, Cui, Y, Damaskos, D, de' Angelis, N, Delibegovic, S, Demetrashvili, Z, De Simone, B, de Jonge, S, Dhingra, S, Di Bella, S, Di Marzo, F, Di Saverio, S, Dogjani, A, Duane, T, Enani, M, Fugazzola, P, Galante, J, Gachabayov, M, Ghnnam, W, Gkiokas, G, Gomes, C, Griffiths, E, Hardcastle, T, Hecker, A, Herzog, T, Kabir, S, Karamarkovic, A, Khokha, V, Kim, P, Kim, J, Kirkpatrick, A, Kong, V, Koshy, R, Kryvoruchko, I, Inaba, K, Isik, A, Iskandar, K, Ivatury, R, Labricciosa, F, Lee, Y, Leppaniemi, A, Litvin, A, Luppi, D, Machain, G, Maier, R, Marinis, A, Marmorale, C, Marwah, S, Mesina, C, Moore, E, Moore, F, Negoi, I, Olaoye, I, Ordonez, C, Ouadii, M, Peitzman, A, Perrone, G, Pikoulis, M, Pintar, T, Pipitone, G, Podda, M, Rasa, K, Ribeiro, J, Rodrigues, G, Rubio-Perez, I, Sall, I, Sato, N, Sawyer, R, Segovia Lohse, H, Sganga, G, Shelat, V, Stephens, I, Sugrue, M, Tarasconi, A, Tochie, J, Tolonen, M, Tomadze, G, Ulrych, J, Vereczkei, A, Viaggi, B, Gurioli, C, Casella, C, Pagani, L, Baiocchi, G, Catena, F, HUS Abdominal Center, II kirurgian klinikka, and University of Helsinki

Subjects
Review, DAMAGE CONTROL LAPAROTOMY, Intra-abdominal infections, Peritonitis, Sepsis, Anti-Bacterial Agents, Critical Pathways, Humans, Treatment Outcome, Anti-Infective Agents, Intraabdominal Infections, 0302 clinical medicine, PERFORATED DIVERTICULITIS, Medicine, LAPAROSCOPIC CHOLECYSTECTOMY, Surgical approach, Iais, biology, Peritoniti, Anti-Infective Agents / therapeutic use, Medical emergencies. Critical care. Intensive care. First aid, 3. Good health, SURGICAL-TREATMENT, 030220 oncology & carcinogenesis, embryonic structures, Emergency Medicine, 030211 gastroenterology & hepatology, KLEBSIELLA-PNEUMONIAE, medicine.medical_specialty, RD1-811, Sepsi, MEDLINE, ANTIBIOTIC-THERAPY, 03 medical and health sciences, Intra-abdominal infection, Emergency surgery, Effective treatment, COMPUTED-TOMOGRAPHY, Intensive care medicine, Anti-Bacterial Agents / therapeutic use, Task force, business.industry, RC86-88.9, Abdominal Infection, SEPTIC SHOCK, Intraabdominal Infections / surgery, 3126 Surgery, anesthesiology, intensive care, radiology, biology.organism_classification, Review article, PRIMARY RESECTION, ACUTE COLONIC DIVERTICULITIS, Surgery, business, Intraabdominal Infections / drug therapy
Abstract

Intra-abdominal infections (IAIs) are common surgical emergencies and have been reported as major contributors to non-trauma deaths in hospitals worldwide. The cornerstones of effective treatment of IAIs include early recognition, adequate source control, appropriate antimicrobial therapy, and prompt physiologic stabilization using a critical care environment, combined with an optimal surgical approach. Together, the World Society of Emergency Surgery (WSES), the Global Alliance for Infections in Surgery (GAIS), the Surgical Infection Society-Europe (SIS-E), the World Surgical Infection Society (WSIS), and the American Association for the Surgery of Trauma (AAST) have jointly completed an international multi-society document in order to facilitate clinical management of patients with IAIs worldwide building evidence-based clinical pathways for the most common IAIs. An extensive non-systematic review was conducted using the PubMed and MEDLINE databases, limited to the English language. The resulting information was shared by an international task force from 46 countries with different clinical backgrounds. The aim of the document is to promote global standards of care in IAIs providing guidance to clinicians by describing reasonable approaches to the management of IAIs.

Published
2021

18. Oral manifestations in melanoma patients treated with target or immunomodulatory therapies

Author

Carlotta Gurioli, Elena Campione, Martina Mussi, Martina Lambertini, Aurora Alessandrini, Emanuela Marcelli, Emi Dika, Simone Ribero, Bruna Gouveia, Barbara Melotti, Dika E., Lambertini M., Gouveia B., Mussi M., Marcelli E., Campione E., Gurioli C., Melotti B., Alessandrini A., and Ribero S.

Subjects
Oncology, Adverse event, Oral, Target, medicine.medical_specialty, medicine.medical_treatment, lcsh:Medicine, Review, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Antigen, Internal medicine, Medicine, Cytotoxic T cell, Adverse effect, Melanoma, Pigmentation disorder, business.industry, lcsh:R, General Medicine, Immunotherapy, Hyperplasia, medicine.disease, 030220 oncology & carcinogenesis, adverse event, immunotherapy, melanoma, oral, target, business, Tyrosine kinase
Abstract

Background: BRAF (v-raf murine sarcoma viral oncogene homolog B1) and MEK (mitogen activated protein kinase) inhibitors, as well as immunotherapy against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death 1 (PD-1) receptor and its ligand (PD-L1), have shown good results in improving the disease-free survival of patients with metastatic melanoma (MM). The aim of this review is to summarize the main oral adverse events (oAEs) occurring in patients undergoing target or immunotherapy. We proposed two separate sections: oAEs during the treatment with (1) target therapies with BRAF and MEK inhibitors and tyrosine kinase inhibitors (gingival hyperplasia, pigmentation disorders, squamo-proliferative lesions) and (2) immunotherapies with CTLA-4 or PD1 inhibitors (lichenoid reactions, immuno-bullous reactions, xerostomia and other reactions). Adverse events frequently include oAEs, although these are often misdiagnosed and under-reported. Indeed, the oral cavity is not routinely evaluated during clinical practice. The symptomatology related to oAEs is significant since it may represent the first manifestation of a severe systemic reaction, possibly leading to difficulties in nutrition with a consequent impact on patients’ quality of life. A careful examination of the oral cavity is recommended during the evaluation of oncologic patients in order to promptly detect the onset of new manifestations.

Published
2021

19. Basaloid follicular hamartomas in pediatric Basal Cell Nevus Syndrome: A diagnostic challenge

Author

Giulia Veronesi, Cosimo Misciali, Costantino Ricci, Carlotta Gurioli, Francesca Besagni, Emi Dika, Barbara Corti, Iria Neri, Besagni F., Dika E., Ricci C., Misciali C., Veronesi G., Corti B., Gurioli C., and Neri I.

Subjects
basal cell carcinomas, basaloid follicular hamartomas, Pathology, medicine.medical_specialty, congenital, hereditary, and neonatal diseases and abnormalities, skin, Skin Neoplasms, PTCH, Hamartoma, Concise Communications, Hyperkeratosis, Basal Cell Nevus Syndrome, Dermatology, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Germline mutation, basal cell carcinoma, Follicular phase, medicine, Humans, basaloid follicular hamartoma, Multiple Basal Cell Carcinomas, skin and connective tissue diseases, Child, business.industry, Concise Communication, General Medicine, medicine.disease, Patched-1 Receptor, PTCH1, Carcinoma, Basal Cell, 030220 oncology & carcinogenesis, Immunohistochemistry, Inherited disease, business, Human
Abstract

Basal Cell Nevus Syndrome (BCNS) is an autosomal dominant inherited disease caused by PTCH1 (9q22.3‐q31) germline mutations. Skin manifestations are mainly characterized by hyperkeratosis of the palms and soles, palmoplantar pits and a strong predisposition to develop multiple basal cell carcinomas (BCCs). Recently, it has been hypothesized that basaloid follicular hamartomas (BFH) could be included in BCNS skin features. We present three pediatric cases of GS with BCCs and BFHs. Clinical, dermoscopic and immunohistochemical tools are reported.

Published
2021

20. Case of melorheostosis associated with ipsilateral verrucous epidermal nevus, linear connective tissue nevus, diffuse hyperpigmentation and hypertrichosis: A fortuitous coincidence?

Author

Luca Sangiorgi, Elena Pedrini, Cosimo Misciali, Carlotta Baraldi, Morena Tremosini, Annalisa Patrizi, Carlotta Gurioli, Ambra Di Altobrando, Iria Neri, Maria Gnoli, Di Altobrando A., Neri I., Gurioli C., Misciali C., Baraldi C., Pedrini E., Gnoli M., Tremosini M., Sangiorgi L., and Patrizi A.

Subjects
Hypertrichosis, Hyperostosis, medicine.medical_specialty, Skin Neoplasms, Melorheostosis, Dermatology, Nevus, Sebaceous of Jadassohn, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Hyperpigmentation, Nevus sebaceus, medicine, Humans, Linear Scleroderma, skin and connective tissue diseases, Child, Nevus, Connective tissue nevus, integumentary system, business.industry, hypertrichosi, General Medicine, medicine.disease, connective tissue nevu, melorheostosi, 030220 oncology & carcinogenesis, medicine.symptom, verrucous epidermal nevus, business, Unilateral nevoid telangiectasia
Abstract

Melorheostosis (MEL) is a rare benign bone disorder that can be associated with several anomalies, including vascular abnormalities, nevus sebaceus, unilateral nevoid telangiectasia, linear scleroderma and hypertrichosis. We report the case of a 6-year-old patient who showed an unusual co-occurrence of bone hyperostosis and different skin lesions affecting the same side of the body: MEL, verrucous epidermal nevus, connective tissue nevus, linear scleroderma-like disorder, hyperpigmentation and hypertrichosis. The spatial co-occurrence of these conditions made us speculate as to whether they originated from a common genetic mechanism or if their co-occurrence was completely accidental.

Published
2019

21. Congenital multiple median raphe cysts of the penis and scrotum

Author

Michele Libri, Giulia Maria Ravaioli, Iria Neri, Mario Lima, Annalisa Patrizi, Carlotta Gurioli, Patrizi A., Neri I., Lima M., Libri M., Gurioli C., and Ravaioli G.M.

Subjects
medicine.anatomical_structure, Median raphe, business.industry, Pediatrics, Perinatology and Child Health, Scrotum, medicine, Anatomy, Median raphe cysts, business, Penis
Abstract

Median raphe cysts (MRCs) are uncommon benign lesions of the male genitalia that develop from the median raphe. They can occur anywhere from the perianal region to the scro- tum and distal penis, placed in a midline position. MRCs are mostly congenital and are believed to result from altered intra-uterine embryonic development. Their diagnosis is rare in childhood.

Published
2019

22. Cutaneous carcinogenic risk evaluation in 375 patients treated with narrowband-UVB phototherapy: A 15-year experience from our Institute

Author

Carlotta Gurioli, Giulia Maria Ravaioli, Andrea Gazzola, Annalisa Patrizi, Beatrice Raone, and Raone B, Patrizi A, Gurioli C, Gazzola A, Ravaioli GM.

Subjects
Adult, Male, medicine.medical_specialty, Skin Neoplasms, Adolescent, Immunology, Dermatology, Vitiligo, macromolecular substances, Risk Assessment, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Psoriasis, medicine, Immunology and Allergy, Narrowband UVB phototherapy, Humans, Radiology, Nuclear Medicine and imaging, Basal cell carcinoma, 030212 general & internal medicine, Child, Carcinogen, Aged, Retrospective Studies, Aged, 80 and over, integumentary system, business.industry, Melanoma, General Medicine, Middle Aged, medicine.disease, University hospital, narrowband-ultraviolet B, Risk evaluation, skin cancers, Female, Ultraviolet Therapy, sense organs, business, phototherapy
Abstract

Background Narrowband-ultraviolet B (NB-UVB) is widely used for the treatment of several dermatological diseases. A cutaneous carcinogenic effect has been hypothesized, but not proved. Methods We retrospectively reviewed the data of patients treated with NB-UVB between January 1998 and December 2013 at the Dermatology Unit of our University Hospital, to evaluate the cutaneous carcinogenic risk of NB-UVB. Results 375 patients were included, each receiving a mean follow-up of 6.9 years. Vitiligo and psoriasis were the most common diseases. 19 non-melanoma skin cancers (NMSCs) were diagnosed in 8 patients, after a mean latency of 5.2 years after the first radiation. No malignant melanoma (MM) was observed. The incidence rates of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) were 620.2/100 000 p/y and 116.3/100 000 p/y. NMSCs were more frequent in patients affected by psoriasis (p = 0.0232), with older age at the first radiation (mean = 68.8 years, p = 0.0001). Conclusion Despite the small number of patients and limited follow-up, our data suggest that NB-UVB may trigger cutaneous carcinogenesis, mainly in patients at risk for NMSCs, increasing their personal risk for single and multiple neoplasms, usually superficial BCCs. MM risk does not seem to be enhanced. This article is protected by copyright. All rights reserved.

Published
2018

23. Sequential monitoring of pigmented lesions during dabrafenib treatment: a prospective study and a literature overview

Author

Alessandro Traniello Gradassi, Emi Dika, Annalisa Patrizi, Pier Alessandro Fanti, Carlotta Gurioli, Martina Lambertini, Marco Adriano Chessa, Francesca Sperandi, Bianca Maria Piraccini, Barbara Melotti, Giulia Maria Ravaioli, Dika E., Lambertini M., Fanti P.A., Piraccini B.M., Gurioli C., Ravaioli G.M., Chessa M.A., Traniello Gradassi A., Melotti B., Sperandi F., and Patrizi A.

Subjects
Male, medicine.medical_specialty, Skin Neoplasms, Hyperkeratosis, Antineoplastic Agents, Dermatology, Adverse effect, Skin Diseases, Follow-Up Studie, Antineoplastic Agent, Oxime, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Hyperpigmentation, Oximes, medicine, Humans, Molecular Targeted Therapy, Prospective Studies, Neoplasm Metastasis, Prospective cohort study, Imidazole, Melanoma, Nevus, Pigmented, business.industry, Dabrafenib, Skin Disease, Imidazoles, medicine.disease, Neoplasm Metastasi, Prospective Studie, Histopathology, Female, Every Four Weeks, medicine.symptom, business, medicine.drug, Human, Follow-Up Studies
Abstract

BACKGROUND: Targeted therapies in melanoma have shown clinical benefit in incrementing the overall survival of metastatic patients. However, cutaneous adverse events have been frequently associated with these drugs. METHODS: We report our experience in the management of patients treated with dabrafenib for metastatic melanoma, focusing on the monitoring of pigmented lesions. Dermatologic evaluation was performed during the first visit, at the start of each treatment and subsequently after every four weeks. Global nevi count, videodermoscopy of suspected lesions, and surgical excisions when necessary were performed at the beginning of the treatment and every fourth week. All other cutaneous adverse events (cAEs) were noted and documented. Eleven patients were included. RESULTS: The most important cAEs included palmo-plantar hyperkeratosis, diffuse xerosis and pigmented lesion changes. Regarding the latter, in 6 patients, especially in the first months of treatment, we observed hyperpigmentation and hyperkeratosis of the nevi, of the pigmented mucosae and, in one patient, hyperkeratotic changes on a cutaneous metastasis. Histopathology of the excised lesions showed one ex novo melanoma occurrence and benign changes to pre-existing nevi. CONCLUSIONS: The awareness of the importance of sequential monitoring of pigmented lesions, with particular attention to the lesions of new onset, is crucial for the best management of these complex patients.

Published
2017

24. Self-inflicted skin lesions and trichotillomania due to rolled hair

Author

Cosimo Misciali, Carlotta Gurioli, Camilla Loi, Michela Starace, Bianca Maria Piraccini, Annalisa Patrizi, Loi, C, Piraccini, Bm, Misciali, C, Starace, M, Gurioli, C, and Patrizi, A.

Subjects
Self-inflicted skin lesions, medicine.medical_specialty, Infectious Diseases, integumentary system, business.industry, Medicine, Dermatology, sense organs, rolled hair, tricotillomania, business
Abstract

Rolled hairs differ from circle hair because of the presence of keratotic inflammatory follicular lesions and are usually seen in patients with dermatological conditions which apply topical drugs or in patients taking oral steroids with or without cyclosporin A.

Published
2017

25. Congenital mastocytosis

Author

Virdi, A, i. neri, c. gurioli, a. patrizi, Virdi, A, Neri, I., Gurioli, C., and Patrizi, A.

Subjects
pediatric mastocytosis, General Earth and Planetary Sciences, congenital mastocytosi, General Environmental Science
Abstract

Pediatric mastocytosis occurs before the age of 2 years in 90% of cases and is often limited to the skin. PM is congenital in 15-31% of patients. We retrospectively evaluated the features of mastocytosis present at birth in human-subject studies published in PubMed databases between 1917 and 2016, except for those lacking many epidemiologic and follow-up data. We collected data about 45 patients (32 males and 13 females): 27 diffuse cutaneous mastocytosis (DCM), 14 urticaria pigmentosa (UP), 2 solitary mastocytoma and 2 teleangectasia macularis eruptive perstans (TMEP). Extracutaneous involvement was reported in 70.37% of DCM and in 57.14% of UP: the most common were hepato(spleno)megaly or mast cell liver infiltration in DCM and gastrointestinal symptoms in UP. A higher prevalence of DCM in males was reported. DCM is often associated with extracutaneous involvement and, in some cases, with aggressive systemic mastoctytosis or early death. A myeloproliferative disorder may appear concomi tantly or after the improvement of cutaneous manifestations. Regression (partial or total) occurred in 51.11% of all patients. Data about long term prognosis are few because only some cases were monitored after puberty. Spontaneous regression before or at puberty is common in early onset mastocytosis but does not always occur. Reliable prognostic clues are lacking in infants, therefore careful long-term follow-up is essential for the early detection of systemic involvement

Published
2017

26. Phthiriasis palpebrarum

Author

I. Neri, A. Bassi, A. Virdi, C. Gurioli, A. Patrizi, Neri, I, Bassi, A, Virdi, A, Gurioli, C, and Patrizi, A

Subjects
Clinical Pictures, General Medicine
Published
2016

27. The value of transbronchial lung biopsy using jumbo forceps via rigid bronchoscope in diffuse lung disease

Author

Maurizio Zompatori, V. Poletti, Gianluca Casoni, Marco Chilosi, Christian Gurioli, P.N. Chhajed, Dario Olivieri, CASONI GL, GURIOLI C, CHHAJED PN, CHILOSI M, ZOMPATORI M., OLIVIERI D, and POLETTI V.

Subjects
Male, Pulmonary and Respiratory Medicine, medicine.medical_specialty, High-resolution computed tomography, Biopsy, Diffuse infiltrative lung diseases, Forceps, lcsh:Medicine, Balloon, Predictive Value of Tests, Rigid bronchoscope, Bronchoscopy, Humans, Medicine, Fluoroscopy, Lobar Bronchus, Lung, medicine.diagnostic_test, business.industry, lcsh:R, Middle Aged, medicine.anatomical_structure, Transbronchial lung biopsy, Flexible bronchoscope, High resolution computed tomography, Female, Radiology, Lung Diseases, Interstitial, Cardiology and Cardiovascular Medicine, business
Abstract

Background. Transbronchial lung biopsy (TBLB) is a valuable procedure used to obtain a parenchymal specimen in the evaluation of diffuse lung infiltrates. Large forceps are expected to result in larger specimens and improve diagnostic yield. Aim. The objective of this study was to evaluate diagnostic yield of TBLB using large modified flexible gastroenterological forceps (“Jumbo forceps”) compared with ‘normal’ flexible forceps via rigid bronchoscopy in patients with diffuse parenchymal lung disease (DPLD). Methods. The study was a prospective analysis of 95 patients who underwent fluoroscopy guided TBLB over a two year period. Patients with a lung mass or solitary lung nodule undergoing TBLB were excluded. The larger and small forceps were used in a random sequence to avoid a reduction in diagnostic yield of the second series of biopsies related to possible bleeding by first series of biopsies. To minimize the consequence of haemorrhage, we performed every rigid bronchoscopy, placing a non inflated Fogarty balloon and a rigid aspirator (diameter 4 mm) in lobar bronchus near the biopsy segment. The Fogarty balloon has been inflated in case of bleeding. After the bleeding was controlled we continued to operate up to the biopsy segment. Results. Diagnostic yield of TBLB using Jumbo forceps was significantly higher than using normal flexible forceps via rigid bronchoscopy in patients with DPLD (p=0.001). In 74 out of 95 patients (78%) the diagnosis was placed with Jumbo forcep while the smaller forcep was diagnostic in 62 out of 95 patients (65%). Large forceps obtained significantly more tissue than the small forceps; the biopsy specimen taken with normal forcep measured in average 1.4 x 1.0 mm and the larger biopsy taken with jumbo forcep measured in average 2.5 x 1.9 mm (p < 0.005). Conclusion. The use of large biopsy forceps to perform TBLB via rigid bronchoscope can significantly increase diagnostic yield in the pathological diagnosis of diffuse infiltrative lung disease.

Published
2016
Full Text
View/download PDF

29. Detection of D-penicillamine in skin lesions in a case of dermal elastosis after a previous long-term treatment for Wilson's disease

Author

Maria Addolorata Saracino, Carlotta Gurioli, Maria Augusta Raggi, Emanuele Morganti, Riccardo Balestri, Sabina Vaccari, F. De Ponti, Annalisa Patrizi, Francesca Bugamelli, Iria Neri, Neri, I, Gurioli, C, Raggi, M A, Saracino, M A, Morganti, E, Bugamelli, F, de Ponti, F, Vaccari, S, Patrizi, A, and Balestri, R

Subjects
Pathology, medicine.medical_specialty, Long term treatment, Dermatology, Clinical manifestation, Skin Diseases, Hepatolenticular Degeneration, Biopsy, medicine, Humans, Chelating Agents, Chelating Agent, medicine.diagnostic_test, business.industry, Penicillamine, fungi, Middle Aged, medicine.disease, Wilson's disease, Infectious Diseases, Skin biopsy, Female, Skin lesion, business, Elastosis perforans serpiginosa, medicine.drug, Human
Abstract

Background Skin adverse events associated with D-Penicillamine (DPA) are common and multi-faceted, although the presence of DPA or its metabolites has never been documented in the skin, because of inherent difficulties in determining its tissue levels. Thus, the association between DPA and DPA-related dermatoses has been only hypothesized on the basis of careful history, clinical observation and typical histopathological findings. Objective To detect DPA in biopsy specimens in a unique case of 25-year-late-onset elastosis perforans serpiginosa and pseudo-pseudoxanthoma elasticum associated with a history of long-term high dose DPA, by applying a recently described analytical method to assess the presence of DPA in skin. Methods We used a reliable analytical method based on high-performance liquid chromatography coupled with amperometric detection to look for the presence of DPA in skin biopsy specimens. Results A chromatographic peak corresponding to DPA was evidenced in some affected skin samples collected from the patient. Conclusion We documented the effective presence and the persistence after 25 years of DPA in the skin of a woman affected by elastotic cutaneous change due to a long-term therapy with DPA. This report provides further evidence of the relationship between DPA deposit in affected skin and clinical manifestation.

Published
2015

30. Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study - il AD (Italian landscape atopic dermatitis).

Author

Gargiulo L, Ibba L, Alfano A, Malagoli P, Amoruso F, Balato A, Barei F, Burroni AG, Caccavale S, Calzavara-Pinton P, Esposito M, Fargnoli MC, Ferrucci SM, Foti C, Girolomoni G, Gola M, Guanti MB, Gurioli C, Magliulo M, Maurelli M, Morrone P, Musumeci ML, Napolitano M, Ortoncelli M, Patruno C, Piraccini BM, Pezzolo E, Ribero S, Rossi M, Savoia P, Sciarrone C, Tirone B, Vaccino M, Veronese F, Costanzo A, and Narcisi A

Subjects
Humans, Retrospective Studies, Female, Male, Adult, Middle Aged, Treatment Outcome, Italy, Pyrimidines adverse effects, Pyrimidines administration & dosage, Sulfonamides therapeutic use, Sulfonamides adverse effects, Aged, Young Adult, Dermatitis, Atopic drug therapy, Dermatitis, Atopic pathology, Severity of Illness Index
Abstract

Aim: Abrocitinib is a JAK-1 inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD). We conducted a 16-week multicenter retrospective study to assess the short-term effectiveness and safety of abrocitinib in patients with moderate-to-severe AD., Our retrospective study included 85 adult patients from 14 Italian Dermatology Units affected by moderate-to-severe AD treated with abrocitinib 100/200 mg., Methods: Effectiveness of abrocitinib at weeks 4 and 16 was assessed by using the Eczema Area and Severity Index (EASI), the Investigator Global Assessment (IGA), the peak pruritus and sleep- Numerical Rating Scale (PP-NRS and S-NRS, respectively)., Results: At week 16, improvement of at least 90% in EASI (EASI90) and IGA 0/1 was observed in 49.4% and 61.2% of patients, respectively. A reduction of at least 4 points in PP-NRS and S-NRS compared with baseline was achieved by 70.6% of patients for both endpoints. No significant safety reports were observed during the study period. Naïve patients had better rates of EASI 90 compared to patients who previously failed dupilumab. Conclusion: Our data confirm the effectiveness of abrocitinib in a real-world setting with better clinical responses at weeks 4 and 16, compared with Phase-III clinical trials. Longer analyses are required to further establish the safety profile of abrocitinib.

Published
2024
Full Text
View/download PDF

31. Effective response to upadacitinib in patients affected by prurigo nodularis and by atopic dermatitis with a predominant prurigo nodularis pattern: A multicenter case series study.

Author

Pezzolo E, Narcisi A, Gargiulo L, Di Lernia V, Napolitano M, Patruno C, Ribero S, Ortoncelli M, Foti C, Romita P, Gurioli C, Schena D, Ferrucci SM, Barei F, Amoruso GF, Russo F, and Naldi L

Abstract

Competing Interests: Conflicts of interest Dr Pezzolo has been consultant and speaker for Sanofi Genzyme, AbbVie, Leo Pharma, Novartis, Janssen, Almirall, Pfizer, Galderma, and Boehringer Ingelheim. Dr Narcisi has served on advisory boards, received honoraria for lectures and research grants from Almirall, AbbVie, Leo Pharma, Celgene, Eli Lilly, Janssen, Novartis, Sanofi Genzyme, Amgen, and Boehringer Ingelheim. Dr Gargiulo has served on advisory boards and received honoraria for lectures from Almirall, Pfizer, and UCB. Dr Di Lernia has been an adviser for AbbVie, Almirall, Amgen, and Janssen, is a consultant for AbbVie and Novartis, and has been a principal investigator for Almirall, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and Sanofi. Dr Napolitano acted as a speaker or consultant for AbbVie, Amgen, Pfizer, Eli Lilly, Sanofi, and Leo Pharma. Dr Patruno acted as a speaker or consultant for AbbVie, Eli Lilly, Leo Pharma, Novartis, and Sanofi. Drs Ribero and Ortoncelli have received research and travel grant from AbbVie, Almirall, Eli Lilly, Leo Pharma, Novartis Pfizer, and Sanofi. Dr Ferrucci has served as speaker, principal investigator, or member of advisory boards for AbbVie, Amgen, Galderma, Eli Lilly, Pfizer, Leo Pharma, Novartis, Menarini, Sanofi Regeneron, and Almirall. Dr Russo acted as speaker and consultant for Novartis, Sanofi, Leo Pharma, and AbbVie, outside the submitted work. Dr Naldi has been consultant and speaker for AbbVie, Almirall, Bristol Myers Squibb, Janssen, Leo Pharma, Novartis, and Sanofi Genzyme. Drs Foti, Romita, Gurioli, Schena, Barei, and Amoruso have no conflicts of interest to declare.

Published
2024
Full Text
View/download PDF

32. Dupilumab and Alopecia Areata: A Possible Combined or Disturbance Therapy? A Review of The Literature.

Author

Starace M, Cedirian S, Quadrelli F, Pampaloni F, Brunetti T, Chessa MA, Gurioli C, Piraccini BM, and Neri I

Abstract

Introduction: Dupilumab, a monoclonal antibody targeting IL-4 receptor subunit alpha, treats atopic dermatitis (AD) and may impact alopecia areata (AA). AA involves Th1-driven immune activity, and recent studies suggest a role for Th2 pathways. Dupilumab's effects on AA are mixed, with reports of both improvement and worsening., Objectives: This study aims to review the effects of dupilumab on AA in patients with AD, analyzing literature to understand cases of improvement or worsening and identifying contributing factors., Methods: A literature review was conducted using articles in platforms such as PubMed, Scopus, and Web of Science written up to April 2024, focusing on studies involving AA, AD, and dupilumab. Articles were analyzed for patient demographics, disease characteristics, and responses to treatment., Results: Out of 35 articles reviewed, 13 AA cases worsened after dupilumab (mean age 32.8; mostly males with patchy alopecia), and 38 cases showed improvement (mean age 27.6; majority females, varying AA types). Full hair regrowth occurred in 11 improved cases, while 9 had partial regrowth., Conclusions: Dupilumab shows dual effects on AA, influenced by Th1/Th2 immune profiles. Worsening was more common in males with Th1-driven AA, while females with Th2-skewed AA saw improvement. Factors like age, disease severity, and IgE levels may affect outcomes, suggesting a need for personalized treatment approaches for AA patients with AD.

Published
2024
Full Text
View/download PDF

33. Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: A nationwide retrospective cohort study.

Author

Avallone G, Cavallo F, Tancredi A, Maronese CA, Bertello M, Fraghì A, Conforti C, Calabrese G, Di Nicola MR, Oddenino GA, Gargiulo L, Gori N, Loi C, Romita P, Piras V, Bonzano L, Tolino E, Paolino G, Napolitano M, Patruno C, Nettis E, Ferreli C, Roccuzzo G, Marozio L, Silvio M, Russo F, Bettolini L, Gallo R, Mercuri SR, Mastorino L, Rossi M, Zalaudek I, Argenziano G, Trave I, Costanzo A, Chiricozzi A, Gurioli C, Foti C, Potenza C, Ferrucci SM, Balato A, Parodi A, Marzano AV, Ortoncelli M, Ribero S, and Quaglino P

Subjects
Humans, Pregnancy, Female, Retrospective Studies, Adult, Young Adult, Adolescent, Middle Aged, Infant, Newborn, Severity of Illness Index, Italy epidemiology, Dermatitis, Atopic drug therapy, Antibodies, Monoclonal, Humanized adverse effects, Antibodies, Monoclonal, Humanized therapeutic use, Pregnancy Complications drug therapy, Pregnancy Outcome
Abstract

Background: There is limited epidemiological evidence on outcomes associated with dupilumab exposure during pregnancy; monitoring pregnancy outcomes in large populations is required., Objective: To investigate the potential association between exposure to dupilumab in pregnant women with atopic dermatitis and any adverse pregnancy, neonatal, congenital and post-partum outcomes., Methods: We performed a multicentre retrospective cohort study across 19 Italian tertiary referral hospital. Childbearing women were eligible if aged 18-49 years and carried out the pregnancy between 1 October 2018 and 1 September 2022., Results: We retrospectively screened records of 5062 patients receiving dupilumab regardless of age and gender, identifying 951 female atopic dermatitis patients of childbearing age, 29 of whom had been exposed to the drug during pregnancy (3%). The median duration of dupilumab treatment prior to conception was 22.5 weeks (range: 3-118). The median time of exposure to the drug during pregnancy was 6 weeks (range: 2-24). All the documented pregnancies were unplanned, and the drug was discontinued in all cases once pregnancy status was reported. The comparison of the study cohort and the control group found no significant drug-associated risk for adverse pregnancy, congenital, neonatal or post-partum outcomes. The absence of a statistically significant effect of exposure on the event was confirmed by bivariate analysis and multivariate analysis adjusted for other confounding factors., Conclusions: This cohort of pregnant patients exposed to dupilumab adds to the existing evidence concerning the safety of biologic agents in pregnancy. No safety issues were identified regarding the primary outcome assessed. In clinical practice, these data provide reassurance in case of dupilumab exposure during the first trimester. However, the continuous use of dupilumab throughout pregnancy warrants further research., (© 2024 European Academy of Dermatology and Venereology.)

Published
2024
Full Text
View/download PDF

34. Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: A multicenter retrospective study.

Author

Avallone G, Mastorino L, Tavoletti G, Macagno N, Barei F, Schena D, Rossi M, Magnaterra E, Antonelli F, Babino G, Viola R, Gargiulo L, Conforti C, Rapparini L, Errichetti E, Patruno C, Ruggiero P, Roccuzzo G, Maronese CA, Girolomoni G, Gola M, Chiricozzi A, Balato A, Ambrogio F, Narcisi A, Zalaudek I, Gurioli C, Napolitano M, Marzano AV, Foti C, Costanzo A, Piraccini BM, Ferrucci SM, Ortoncelli M, Quaglino P, and Ribero S

Subjects
Humans, Retrospective Studies, Treatment Outcome, Janus Kinase Inhibitors adverse effects, Dermatitis, Atopic drug therapy, Acne Vulgaris drug therapy, Heterocyclic Compounds, 3-Ring
Abstract

Competing Interests: Conflicts of interest None disclosed.

Published
2024
Full Text
View/download PDF

38. A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis.

Author

Stingeni L, Bianchi L, Antonelli E, Caroppo ES, Ferrucci SM, Gurioli C, Ortoncelli M, Fabbrocini G, Nettis E, Schena D, Napolitano M, Gola M, Bonzano L, Rossi M, Belloni Fortina A, Balato A, Peris K, Foti C, Guarneri F, Romanelli M, Patruno C, Savoia P, Esposito M, Russo F, Errichetti E, Bianchelli T, Bianchi L, Pellacani G, Feliciani C, Offidani A, Corazza M, Micali G, Milanesi N, Malara G, Chiricozzi A, Tramontana M, and Hansel K

Subjects
Humans, Adolescent, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal adverse effects, Treatment Outcome, Severity of Illness Index, Double-Blind Method, Dermatitis, Atopic drug therapy
Published
2023
Full Text
View/download PDF

39. Medical Thoracoscopy and Intrapleural Fibrinolytic Therapy for the Management of Pleural Empyema: A Cohort Study.

Author

Ravaglia C, Ghirotti C, Puglisi S, Piciucchi S, Gurioli C, Fabbri E, Sultani F, Martinello S, Corso RM, Maitan S, Sambri V, Stella F, and Poletti V

Subjects
Humans, Cohort Studies, Retrospective Studies, Thoracic Surgery, Video-Assisted adverse effects, Thrombolytic Therapy adverse effects, Thoracoscopy methods, Empyema, Pleural drug therapy, Empyema, Pleural surgery
Abstract

Background: Pleural empyema is associated with relevant morbidity and mortality, and it may be classified, according to evolution and ultrasound, into three stages: stage I (free-flowing effusion), stage II (viscous effusion with the tendency to loculate), and stage III (organizing phase). According to guidelines, antibiotic therapy and pleural drainage are recommended, with surgery being performed when patients fail and/or in case of organized empyema., Objectives: The aim of the study was to report the efficacy and safety of medical thoracoscopy in patients with pleural empyema stratified by chest ultrasound., Method: Observational retrospective cohort study analyzing patients with pleural empyema treated with medical thoracoscopy. Procedure success and mortality were evaluated at 30 days and 90 days after the procedure; complications were also reported., Results: 131 patients were included. Intrapleural fibrinolytic therapy was performed thereafter in the majority of cases. Medical thoracoscopy was considered successful without subsequent intervention in 99 patients (76%); 19 patients (15%) underwent a second procedure (drainage, thoracoscopy, video-assisted thoracic surgery, or thoracotomy); and 6 patients (5%) died of the evolution of empyema. Patients treated in stages I and II showed significantly better post-procedure results compared with patients treated in stage III (100%, 83.3%, and 58.1%, respectively). Thoracoscopy complications were observed in 18 patients and were reversible in all cases., Conclusions: Patients with pleural empyema treated in earlier stages (free-flowing or multiloculated effusion) with medical thoracoscopy show significantly better results than patients treated in later stages (organized empyema). This approach is safe, minimally invasive, and efficient in these patients with disease having relevant mortality; however, patient selection remains essential., (© 2022 S. Karger AG, Basel.)

Published
2023
Full Text
View/download PDF

41. WSES/GAIS/SIS-E/WSIS/AAST global clinical pathways for patients with intra-abdominal infections.

Author

Sartelli M, Coccolini F, Kluger Y, Agastra E, Abu-Zidan FM, Abbas AES, Ansaloni L, Adesunkanmi AK, Atanasov B, Augustin G, Bala M, Baraket O, Baral S, Biffl WL, Boermeester MA, Ceresoli M, Cerutti E, Chiara O, Cicuttin E, Chiarugi M, Coimbra R, Colak E, Corsi D, Cortese F, Cui Y, Damaskos D, De' Angelis N, Delibegovic S, Demetrashvili Z, De Simone B, de Jonge SW, Dhingra S, Di Bella S, Di Marzo F, Di Saverio S, Dogjani A, Duane TM, Enani MA, Fugazzola P, Galante JM, Gachabayov M, Ghnnam W, Gkiokas G, Gomes CA, Griffiths EA, Hardcastle TC, Hecker A, Herzog T, Kabir SMU, Karamarkovic A, Khokha V, Kim PK, Kim JI, Kirkpatrick AW, Kong V, Koshy RM, Kryvoruchko IA, Inaba K, Isik A, Iskandar K, Ivatury R, Labricciosa FM, Lee YY, Leppäniemi A, Litvin A, Luppi D, Machain GM, Maier RV, Marinis A, Marmorale C, Marwah S, Mesina C, Moore EE, Moore FA, Negoi I, Olaoye I, Ordoñez CA, Ouadii M, Peitzman AB, Perrone G, Pikoulis M, Pintar T, Pipitone G, Podda M, Raşa K, Ribeiro J, Rodrigues G, Rubio-Perez I, Sall I, Sato N, Sawyer RG, Segovia Lohse H, Sganga G, Shelat VG, Stephens I, Sugrue M, Tarasconi A, Tochie JN, Tolonen M, Tomadze G, Ulrych J, Vereczkei A, Viaggi B, Gurioli C, Casella C, Pagani L, Baiocchi GL, and Catena F

Subjects
Anti-Bacterial Agents therapeutic use, Critical Pathways, Humans, Treatment Outcome, Anti-Infective Agents therapeutic use, Intraabdominal Infections drug therapy, Intraabdominal Infections surgery
Abstract

Intra-abdominal infections (IAIs) are common surgical emergencies and have been reported as major contributors to non-trauma deaths in hospitals worldwide. The cornerstones of effective treatment of IAIs include early recognition, adequate source control, appropriate antimicrobial therapy, and prompt physiologic stabilization using a critical care environment, combined with an optimal surgical approach. Together, the World Society of Emergency Surgery (WSES), the Global Alliance for Infections in Surgery (GAIS), the Surgical Infection Society-Europe (SIS-E), the World Surgical Infection Society (WSIS), and the American Association for the Surgery of Trauma (AAST) have jointly completed an international multi-society document in order to facilitate clinical management of patients with IAIs worldwide building evidence-based clinical pathways for the most common IAIs. An extensive non-systematic review was conducted using the PubMed and MEDLINE databases, limited to the English language. The resulting information was shared by an international task force from 46 countries with different clinical backgrounds. The aim of the document is to promote global standards of care in IAIs providing guidance to clinicians by describing reasonable approaches to the management of IAIs., (© 2021. The Author(s).)

Published
2021
Full Text
View/download PDF

43. Short anagen syndrome: A case series and algorithm for diagnosis.

Author

Starace M, Gurioli C, Carpanese MA, Bruni F, Piraccini BM, Patrizi A, and Alessandrini A

Subjects
Algorithms, Child, Hair, Humans, Retrospective Studies, Alopecia, Hair Diseases
Abstract

Background: The short anagen syndrome (SAS) is a rare idiopathic pediatric disorder characterized by the short duration of the anagen phase. SAS mainly affects Caucasian children. Parents complain of their child's inability to grow long hair. Topical minoxidil may be an effective treatment for SAS; however, a slow spontaneous improvement is typical., Objective: Our aim was to collect data on out cases of SAS and create an algorithm to facilitate diagnosis of SAS., Methods: A retrospective review of 25 patients with SAS was performed within the Dermatology Department of the University of Bologna. We collected data regarding symptoms, pull test, hair card test, trichoscopy, trichogram, treatments, including biotin and minoxidil, and clinical outcome., Results: Characteristic findings included parental reporting that the hair had not required a haircut, hair card test showing hairs with conical-shaped tips, and hair shafts of different diameters, with more 10%-20% of hair shafts less than 60 μm thick on trichoscopy. Trichogram revealed an increased percentage of telogen hair with normal hair shafts and tapering ends. The mean anagen-to-telogen ratio was 66:34 (normal ratio 90:10)., Conclusion: We developed an algorithm to facilitate the diagnosis of this rare hair disease using clinical examination and invasive and non-invasive testing to differentiate SAS from other forms of pediatric alopecia. In conclusion, the collected data of the therapy showed that biotin alone or in combination with topical minoxidil is an effective treatment for SAS., (© 2021 Wiley Periodicals LLC.)

Published
2021
Full Text
View/download PDF

44. Vulvar vitiligo and lichen sclerosus in children: A clinical challenge.

Author

Veronesi G, Virdi A, Leuzzi M, Gurioli C, Chessa MA, Guglielmo A, and Neri I

Subjects
Child, Female, Humans, Observational Studies as Topic, Skin, Lichen Sclerosus et Atrophicus complications, Lichen Sclerosus et Atrophicus diagnosis, Vitiligo diagnosis, Vulvar Lichen Sclerosus diagnosis
Abstract

Vulvar vitiligo (VV) and vulvar lichen sclerosus (VLS), both feature skin and mucosal hypo-/depigmentation. The aim of this study was to describe the clinical and dermoscopic features of VV and VLS in the pediatric population, providing diagnostic clues, and to define their association. We performed a systematic literature review of the clinical and dermoscopic features of pediatric VV and VLS. An observational study was conducted on children affected by VLS associated with VV, referred to the Dermatology Unit of the Sant'Orsola Polyclinic in Bologna, Italy. Medical history, age at diagnosis, ethnicity, clinical and dermoscopic features, and symptoms were recorded for all patients. 124 cases of VLS and 10 cases of VV were reviewed. Clinical manifestations included hypo-/depigmented patches in both conditions, while ecchymosis/purpura and fissures/erosion were observed in VLS. Symptoms including pruritus, pain, or burning were reported only by VLS patients. In our study five patients with VLS associated with VV were retrieved. Clinical features included well-demarcated depigmented patches in VV and translucent areas, erythema, ecchymoses/purpura, and labial fusion in VLS. Dermoscopy showed white structureless areas with a whipped cream-like appearance, linear or dotted vessels, white chrysalis-like structures, erosion and red-purpuric blotches in VLS and reduced pigment network or pigment absence, intralesional spots of residual pigmentation and telangiectasias in VV. Symptoms were present in all patients. Both VV and VLS show hypo-/depigmented patches. In the presence of associated symptoms, possible VLS should be investigated with clinical and dermoscopic examination to achieve a prompt diagnosis., (© 2021 Wiley Periodicals LLC.)

Published
2021
Full Text
View/download PDF

46. Basaloid follicular hamartomas in pediatric Basal Cell Nevus Syndrome: A diagnostic challenge.

Author

Besagni F, Dika E, Ricci C, Misciali C, Veronesi G, Corti B, Gurioli C, and Neri I

Subjects
Child, Humans, Patched-1 Receptor, Basal Cell Nevus Syndrome, Carcinoma, Basal Cell, Hamartoma, Skin Neoplasms
Abstract

Basal Cell Nevus Syndrome (BCNS) is an autosomal dominant inherited disease caused by PTCH1 (9q22.3-q31) germline mutations. Skin manifestations are mainly characterized by hyperkeratosis of the palms and soles, palmoplantar pits and a strong predisposition to develop multiple basal cell carcinomas (BCCs). Recently, it has been hypothesized that basaloid follicular hamartomas (BFH) could be included in BCNS skin features. We present three pediatric cases of GS with BCCs and BFHs. Clinical, dermoscopic and immunohistochemical tools are reported., (© 2021 The Authors. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results